107 related articles for article (PubMed ID: 27622032)
1. Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.
Ghasemi R; Lazear E; Wang X; Arefanian S; Zheleznyak A; Carreno BM; Higashikubo R; Gelman AE; Kreisel D; Fremont DH; Krupnick AS
Nat Commun; 2016 Sep; 7():12878. PubMed ID: 27650575
[TBL] [Abstract][Full Text] [Related]
2. Altered Expression of Natural Cytotoxicity Receptors and NKG2D on Peripheral Blood NK Cell Subsets in Breast Cancer Patients.
Nieto-Velázquez NG; Torres-Ramos YD; Muñoz-Sánchez JL; Espinosa-Godoy L; Gómez-Cortés S; Moreno J; Moreno-Eutimio MA
Transl Oncol; 2016 Oct; 9(5):384-391. PubMed ID: 27641642
[TBL] [Abstract][Full Text] [Related]
3. Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
Ozaniak A; Vachtenheim J; Lischke R; Bartunkova J; Strizova Z
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440139
[TBL] [Abstract][Full Text] [Related]
4. Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy.
Sousa LM; Almeida JS; Fortes-Andrade T; Santos-Rosa M; Freitas-Tavares P; Casanova JM; Rodrigues-Santos P
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359785
[TBL] [Abstract][Full Text] [Related]
5. Potential Role of Hsp70 and Activated NK Cells for Prediction of Prognosis in Glioblastoma Patients.
Lobinger D; Gempt J; Sievert W; Barz M; Schmitt S; Nguyen HT; Stangl S; Werner C; Wang F; Wu Z; Fan H; Zanth H; Shevtsov M; Pilz M; Riederer I; Schwab M; Schlegel J; Multhoff G
Front Mol Biosci; 2021; 8():669366. PubMed ID: 34079819
[TBL] [Abstract][Full Text] [Related]
6. Prospects for NK Cell Therapy of Sarcoma.
Lachota M; Vincenti M; Winiarska M; Boye K; Zagożdżon R; Malmberg KJ
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322371
[TBL] [Abstract][Full Text] [Related]
7. PD-1-positive Natural Killer Cells have a weaker antitumor function than that of PD-1-negative Natural Killer Cells in Lung Cancer.
Niu C; Li M; Zhu S; Chen Y; Zhou L; Xu D; Xu J; Li Z; Li W; Cui J
Int J Med Sci; 2020; 17(13):1964-1973. PubMed ID: 32788875
[TBL] [Abstract][Full Text] [Related]
8. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
Jewett A
Front Immunol; 2020; 11():1692. PubMed ID: 32754162
[TBL] [Abstract][Full Text] [Related]
9. Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?
De Bruyn C; Baert T; Van den Bosch T; Coosemans A
Curr Oncol Rep; 2020 Jan; 22(2):12. PubMed ID: 31997106
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis.
Jewett A; Kos J; Kaur K; Safaei T; Sutanto C; Chen W; Wong P; Namagerdi AK; Fang C; Fong Y; Ko MW
Mol Ther Oncolytics; 2020 Mar; 16():41-52. PubMed ID: 31930165
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
[TBL] [Abstract][Full Text] [Related]
12. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
[TBL] [Abstract][Full Text] [Related]
13. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
14. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
15. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
[TBL] [Abstract][Full Text] [Related]
16. The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy.
Fortes-Andrade T; Almeida JS; Sousa LM; Santos-Rosa M; Freitas-Tavares P; Casanova JM; Rodrigues-Santos P
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359767
[TBL] [Abstract][Full Text] [Related]
17. Shaping of Natural Killer Cell Antitumor Activity by
Granzin M; Wagner J; Köhl U; Cerwenka A; Huppert V; Ullrich E
Front Immunol; 2017; 8():458. PubMed ID: 28491060
[TBL] [Abstract][Full Text] [Related]
18. Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.
Bücklein V; Adunka T; Mendler AN; Issels R; Subklewe M; Schmollinger JC; Noessner E
Oncoimmunology; 2016 Jul; 5(7):e1178421. PubMed ID: 27622032
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
